33 results about "Cell junction" patented technology

The invention relates to the field of agricultural bioengineering, in particular to application of an oilseed rape BnaA08G0167600WE gene in enhancing pod shattering resistance of oilseed rape. According to the invention, after a transgenic plant is constructed in oilseed rape by utilizing a modern biotechnological means and the oilseed rape gene BnaA08G0167600WE is knocked out, the silique of the mutant is not easy to crack compared with a wild type under the action of external force, and a separation layer and a wood layer of the cross section of the silique of the mutant have more cell connections compared with the wild type, so that the yield of the mutant is improved. And the generation of the mutants provides an important genetic material for further researching the function of the gene and the effect of the gene in the rape.

Described herein, inter alia, are compositions comprising and methods of making and using endothelial cells (ECs) comprising one or more mitophagy-inducing agents (e.g., rapamycin, SKF-96365, lithium, carbamazepine, latrepirdine, spermidine, resveratrol, sodium valproate, trehalose, kaempferol, metformin, AICAR, nilotinib, ambroxol, curcumin, and VL-004). Also described herein, inter alia, are methods vascular cell therapy, promoting blood vessel formation, and increasing vascular development, angiogenesis, and cell junction via administration of a population of ECs comprising a mitophagy-inducing agent (MIA-ECs).

The invention discloses a method for enhancing mechanical force of CAR-T cells on target cells to overcome mechanical immune checkpoints of SFs and application, and relates to the technical field of crossing of immunotherapy and biomechanics, in particular to CAR-T cells targeting fibroblast activated protein. The invention discloses a CAR-T (chimeric antigen receptor T-T) cell and SFs (small-form-factor s) DNA (deoxyribonucleic acid) nano connector for connecting the CAR-T cell with the SFs, the formation of a CAR cluster and mechanical force transmission are promoted by shortening the membrane spacing of an immune synaptic interface to 16-28nm, the DNA nano connector is formed by self-assembling complementary tetrahedral DNA structures, and the TDS comprises a single-stranded DNA vertex S4 with the length of 24-58 nucleotides. According to the method for enhancing the mechanical force of the CAR-T cells on the target cells to overcome the mechanical immune checkpoints of the SFs and the application, the escape and killing problems of the soft target cells are solved, the soft target cells are efficiently removed, and the killing rate of the CAR-T cells treated by DNJ-17 on the SFs is remarkably increased.

Molecular signature of a common alopecia state, associated with cell junctions. The present invention relates to a method for the in vitro prognosis and / or diagnosis of a common alopecia state of the scalp in a subject, in particular androgenetic alopecia, comprising at least one step a) of measuring the level of expression, in a biological sample taken from an area suspected of being an alopecia area or of becoming an alopecia area in said subject, of at least one gene selected from CDH1, ACTB, ACTBL2, TUBB, TUBB2A, GSN, MYO3B, MYO5B, MYO6, DSG2, DSG3, DSG4, DSC2, GJB2, GJA1, GJB6, GJA3, TJP2, CLDN8, CLDN10, CLDN19, and optionally of at least one gene selected from CTNNB1 and CTNND2.The invention also relates to an in vitro method for evaluating the effectiveness of a treatment for a common alopecia condition, a cosmetic treatment method, the use of a modulator of said gene(s) mentioned above, as well as a method for identifying a compound enabling the prevention and / or treatment of a common alopecia condition.

A microfluidic chip may comprise a plurality of separate microfluidic regions formed into a chip substrate. Each microfluidic region may be configured to simulate an organ and may comprise at least one inlet and at least one outlet with a microfluidic channel therebetween. Connecting microfluidic pathways may be provided between the separate microfluidic regions. The connecting microfluidic pathways may be configured to be vascularized. The connecting microfluidic pathways may comprise a surface treatment configured to receive endothelial cells. The surface treatment may comprise an extracellular matrix protein coating. Endothelial cells may be disposed within the connecting microfluidic pathways. The endothelial cells may comprise organ-specific endothelial cells that match an organ simulated by at least one of the separate microfluidic regions. The connecting microfluidic pathways may comprise synthetic microvascular networks having non-linear channels with physiologically relevant geometries. The physiologically relevant geometries may comprise bifurcations, varying cross-sectional areas, and convolutions.

The invention relates to a combined depolymerization therapy for enhancing colorectal cancer radiotherapy sensitivity, and belongs to the technical field of biological medicine. Specifically, the invention provides an application of an LDH / EDTA layered double hydroxide material in preparation of an anti-colorectal cancer drug used in combination with radiotherapy. In order to solve the problem that the curative effect of low-level colorectal cancer is low, the invention provides a combined therapy for enhancing the curative effect of radiotherapy through depolymerization treatment by using a zinc-aluminum layered dihydroxide material loaded with ethylenediaminetetraacetic acid. By adopting the method, the connection between cells can be efficiently destroyed, so that the tumor is loosened, the hypoxic environment of the tumor is improved, the sensitivity of the tumor to radiotherapy is finally enhanced, and the curative effect is further enhanced.

Provided for herein are novel signal peptides that direct an encoded protein to cell junctions, recombinant polypeptides comprising the same, nucleic acid molecules encoding the same, pharmaceutical compositions comprising the same, and methods of use thereof.

The invention provides trispecific antibodies having one binding site binding to a target antigen on a cancer cell, pathogen, infected cell or autoreactive cell, and second and third binding sites binding to CD3 and CD28 respectively. Such antibodies can crosslink CD3 and CD28 on the surface of T cells at the cell-to-cell junction with target cells, and trigger CD3-mediated signal transduction (Signal 1) and costimulatory molecule-mediated signal transduction (Signal 2) for activation of T cells resulting in efficient elimination of target cells.

The present disclosure pertains to universal and adoptable cell culture substrates designed for applications in biology, medicine, pharmaceutics, and other relevant fields. The disclosure particularly focuses on processes and methodologies for manufacturing such substrates, which prove advantageous for both non-neural (cells exhibiting robust adhesion and weak cell-cell junctions, as well as cells with regular adhesion and cell-cell junctions) and neural cell sheet engineering. These substrates aim to enhance cell adhesion, stimulate cell growth, and enable rapid and uniform harvesting of cell sheets. Additionally, the present invention introduces a scaffold-free method for tissue engineering, facilitating the creation of a 2D / 3D neural tissue construct featuring unidirectional neuron bundles.

A microfluidic chip may comprise a plurality of separate microfluidic regions formed into a chip substrate. Each microfluidic region may be configured to simulate an organ and may comprise at least one inlet and at least one outlet with a microfluidic channel therebetween. Connecting microfluidic pathways may be provided between the separate microfluidic regions. The connecting microfluidic pathways may be configured to be vascularized. The connecting microfluidic pathways may comprise a surface treatment configured to receive endothelial cells. The surface treatment may comprise an extracellular matrix protein coating. Endothelial cells may be disposed within the connecting microfluidic pathways. The endothelial cells may comprise organ-specific endothelial cells that match an organ simulated by at least one of the separate microfluidic regions. The connecting microfluidic pathways may comprise synthetic microvascular networks having non-linear channels with physiologically relevant geometries. The physiologically relevant geometries may comprise bifurcations, varying cross-sectional areas, and convolutions.

Provided herein are novel signal peptides that direct encoded proteins to cell junctions, recombinant polypeptides comprising the signal peptides, nucleic acid molecules encoding the recombinant polypeptides, pharmaceutical compositions comprising the nucleic acid molecules, and methods of use thereof.

The invention discloses application of a known compound, namely a thiazole carboxamide derivative (with the CAS number of 933886-42-1), in preparation of a medicine for treating acute lung injury / acute respiratory distress syndrome, the compound is an SLC39A1 agonist, zinc ions entering cells can be effectively increased, and by reducing the expression quantity of lung tissue inflammation genes IL-1beta and TNF-alpha of mice, the lung tissue inflammation genes IL-1beta and TNF-alpha can be effectively inhibited, so that the acute lung injury / acute respiratory distress syndrome can be effectively inhibited, and the acute lung injury / acute respiratory distress syndrome can be effectively inhibited. Therefore, lung cell infiltration in ALI / ARDS mice is reduced, oxidative damage and tissue damage of lung tissue, inflammatory factor expression and cell connection are improved, and a new choice is provided for treatment of ALI / ARDS.

Provided for herein are novel signal peptides that direct an encoded protein to cell junctions, recombinant polypeptides comprising the same, nucleic acid molecules encoding the same, pharmaceutical compositions comprising the same, and methods of use thereof.

The application discloses a kind of high efficiency gentle mammal blastocyst single cell dissociation method.The method includes the following steps: (1) zona pellucida removal: the blastocyst is placed in calcium magnesium table type liquid, and zona pellucida is completely removed by dissolving and physical blowing operation;(2) enzyme digestion incubation: the blastocyst after step (1) is handled and is transferred to 35-37 ℃ pre-equilibrated complex dissociation solution and incubated for 15-30 minutes, during which intermittent blowing is carried out, until the blastocyst is completely dissociated into single cell;(3) washing: the single cell obtained by dissociation is washed using dPBS, and the residual dissociation solution is removed.The method of the application has high efficiency, high activity and simplified operation.The dissociation process is simplified from 3-4 steps to two steps (zona pellucida dissolution+enzyme digestion incubation), the total time is shortened from more than 90 minutes to less than 30 minutes, the dissociation efficiency is significantly improved;Cell viability is increased from about 70% to more than 90%, the cell junction is gently lysed, and cell damage is reduced.

In particular, compositions comprising iPSC-derived parietal cell precursors (iMPCs) generated using NK3 homeobox 1 (NKX3.1; parietal cell fate-determining transcription factor) and methods for their preparation and use are described herein. In addition, in particular, methods for maturing iMPCs into functional parietal cell subtypes, including smooth muscle cells, perivascular cells, and fibroblasts, as well as methods for increasing angiogenesis, angiogenesis, and cell junctions, are described herein. iMPCs mediate the formation of functional blood vessels when transplanted together with endothelial cells (ECs); thus, methods for modeling vascular diseases (e.g., 3D vascular organoids (VOs)) and therapeutic vascularization, comprising a method of administering iMPCs and ECs and a step of administering iMPCs and ECs, are also described herein.

Provided are methods to increase the nephron yield and control over nephron locations in kidney organoids and kidney replacement tissues; the methods achieve spatiotemporal control over the mechanical microenvironment to engineer favorable environments for nephron formation within kidney organoids. This engineered control can be created using microdevices that impose mechanical stress at defined intervals synchronized with cyclical nephron development in vivo, agonists / antagonists of tension-generating biochemical pathways in whole organoids or cells, optogenetic control over tension in stem cell collectives, and / or cell-cell junction mediated transfer of mechanical information between cells, or similar approaches.

The application discloses a kind of peptide functionalized cellulose derivatives targeting A beta and its preparation method and application, belong to the field of biological medicine technology.The peptide functionalized cellulose derivative obtained by connecting A beta targeting peptide with hydroxypropyl cellulose through ester bond can be combined with A beta protein through molecular recognition specificity, and self-assembly is formed into core-shell structure nanomicelle, A beta oligomer is efficiently encapsulated, A beta aggregation and fiberization are inhibited, meanwhile, the interaction between A beta and endothelial cell junction protein is blocked by anti-fouling performance, APEL effect induced by amyloid is inhibited, and the integrity of blood-brain barrier is protected.In addition, the peptide functionalized cellulose derivative has good biocompatibility, can reduce A beta plaque deposition in brain, improve the cognitive function of AD patients, and provides a new type of efficient candidate drug for the treatment of Alzheimer's disease.

The invention belongs to the field of biological medicine, and particularly relates to a bispecific binding protein structure of a T cell connector, nucleic acid, a carrier, a cell and a preparation method and application of the bispecific binding protein structure. The invention provides a bispecific binding protein of a T cell connector, the bispecific binding protein comprises a TCE double antibody structure of an anti-CD3 antibody sequence, a Fab / Fab-Fab Fc structure or a Fab / Fab-scFv Fc structure is used to construct a bispecific antibody of a 2 + 1 valence tumor-associated antigen and a CD3 protein, and the bispecific binding protein has good tumor cell killing activity after being combined with different TAAs.

The invention provides trispecific antibodies having one binding site binding to a target antigen on a cancer cell, pathogen, infected cell or autoreactive cell, and second and third binding sites binding to CD3 and CD28 respectively. Such antibodies can crosslink CD3 and CD28 on the surface of T cells at the cell-to-cell junction with target cells, and trigger CD3-mediated signal transduction (Signal 1) and costimulatory molecule-mediated signal transduction (Signal 2) for activation of T cells resulting in efficient elimination of target cells.

The invention relates to a method for manufacturing a solar cell string, wherein at least two solar cells arranged next to each other are electrically connected. The invention is characterized in that the solar cells are electrically connected by means of a cell connector structure, wherein the cell connector structure is formed with a plurality of linear, parallel cell connection fingers and the cell connection fingers are applied to the two front sides of the adjacent solar cells or the two back sides of the adjacent solar cells by means of a printing process.

The invention belongs to the technical field of organoid, and particularly relates to a core-shell structure vascularized bone organoid and a preparation method and application thereof. The MSCs and the ECs are cultured by adopting an organoid culture mode, the cell spheroid with a'core-shell 'structure is constructed by using the MSCs / ECs with a specific cell proportion, a microenvironment for in-vivo growth of cells can be better simulated, cell-cell connection and a complete extracellular matrix are preserved, the cell spheroid has a structure and a function similar to those of source cells or directionally differentiated stem cells, and the cell spheroid has a good application prospect. And the development process of organs is simulated, so that higher self-renewal and proliferation capabilities are achieved, the metabolic capability of cells is improved, the cell viability is improved, and good proliferation, osteogenesis and vascularization effects are achieved. The vascularized bone organ prepared by the method can be widely applied to preparation of bone repair materials.

Chimeric antigen receptor (CAR) T cells, bispecific adapters that link the CAR-T cells to tumor cells that express carbonic anhydrase IX (CAIX), and methods of treating CAIX-expressing cancers using the same.

Provided herein are novel recombinant polypeptides comprising an endogenous cell junction targeting signal peptide and a payload protein, nucleic acid molecules encoding the recombinant polypeptides, pharmaceutical compositions comprising the nucleic acid molecules, and methods of use thereof.

Housing cover for energy storage module and corresponding energy storage module The present invention relates to a housing cover for a housing (4) for an energy storage module (1), which is intended to receive an arrangement of a plurality of energy storage cells (3), electrically connected to each other by means of cell connectors (2), the energy storage cells (3) forming a degassing surface having degassing openings (301) arranged along the degassing surface, which serve, in the event of an overpressure occurring in a critical situation in the energy storage cell (3) concerned, to allow gases to escape in a controlled manner from the interior of the energy storage cell (3) through the degassing opening (301).According to the invention, the housing cover (402) and the degassing surface form a degassing channel (5) extending towards at least one end of the housing cover (402), preferably towards both ends of the housing cover (402). Figure to be published with the abstract: Fig. 2.

Described herein, inter alia, are compositions comprising and methods of making and using iPSC-derived mural progenitor cells (iMPCs) generated using NK3 Homeobox 1 (NKX3.1; a mural cell fate-determining transcription factor). Also described herein, inter alia, are methods maturing the iMPCs into functional mural cell subtypes, including smooth muscle cells, pericytes, and fibroblasts, as well as methods of increasing vascular development, angiogenesis, and cell junction via the iMPCs. The iMPCs mediate the formation of functional vessels when implanted with endothelial cells (ECs); thus, methods of administering iMPCs and ECs and methods of modeling vascular diseases (e.g., a 3D vascular organoid (VO)) and therapeutic vascularization comprising administering iMPCs and EC are also described herein.

The invention relates to the technical field of nano-drugs, in particular to a difunctional nano-drug based on an autophagy targeting chimera-T cell connector as well as a preparation method and application of the difunctional nano-drug. The bifunctional nano-drug comprises a lipid shell, and an anti-CD3 antibody is coupled to the lipid shell; a T cell receptor targeting mutant p53 protein is inserted into the lipid shell; a medicine KPY is encapsulated in the lipid shell; and PFP is also encapsulated in the lipid shell. The nano-drug specifically recognizes a KRAS / TP53 mutant tumor through a surface-anchored T cell receptor, and low-intensity focused ultrasound is utilized to promote phase change of PFP to realize release of KPY at a tumor site so as to induce degradation of intracellular KRAS; and the CD3 antibody activates the CD8 + T cells to generate an extracellular immune activation effect. According to the technical scheme, the technical problem that in the prior art, targeted drugs for KRAS / TP53 co-mutation related tumors are lacked can be solved, and ideal application and popularization prospects are achieved.

Provided for herein are novel recombinant polypeptides comprising endogenous cell junction targeting signal peptides and a payload protein, nucleic acid molecules encoding the same, pharmaceutical compositions comprising the same, and methods of use thereof.

Chimeric antigen receptor (CAR)-T cells, bispecific adapters that link CAR-T cells to tumor cells and / or cancer-associated fibroblasts (CAF), and methods of treating cancer using the same.

The invention belongs to the technical field of organic compounding, and the prepared stem cell membrane can completely retain cell surface protein, extracellular matrix and intercellular tight connection, and is beneficial to enhancing stem cell activity and maintaining local effective cell concentration. Through laminated construction of the three-dimensional bionic tissue, animal in-vivo experiment results show that regeneration of bone tissues in a defect area can be remarkably promoted, and the method has a wide application prospect.